---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-075915"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:34:05.609087+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# BioXcel presents at-home BXCL501 market opp: patients would use in 80% of episodes

## Summary
- Market research shows ~3 episodes/month (36/year) per patient, vs prior 23M annual episodes estimate from claims data.
- HCPs would prescribe BXCL501 for ~16% of their bipolar/schizophrenia patients based on target product profile.
- Patients report they would use BXCL501 in 80% of at-home agitation episodes; pricing could reach $1,400+ per prescription.
- At-home setting has no approved treatments; BXCL501 targets early intervention to prevent escalation.
- SERENITY At-Home Phase 3 trial data (2,200+ episodes collected) results are upcoming.

## SEC filing metadata
- accession: 0001104659-25-075915
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925075915/0001104659-25-075915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925075915/tm2523088d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-075915
- JSON: https://secwatch.observer/filing/0001104659-25-075915.json
- Plain text: https://secwatch.observer/filing/0001104659-25-075915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.